Research programme: respiratory disorder therapeutics - Pulmatrix

Drug Profile

Research programme: respiratory disorder therapeutics - Pulmatrix

Alternative Names: Fluticasone/salmeterol dry powder - Pulmatrix; Levofloxacin dry powder - Pulmatrix; PUR 0400; PUR 0500; PUR 0600; PUR 0700; PUR 1000; PUR 113; PUR 1500; PUR 1700; Salmeterol/fluticasone dry powder - Pulmatrix; SD 101 - Pulmatrix; SD 102

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pulmatrix
  • Class Androstadienes; Anti-inflammatories; Biological proteins; Fluoroquinolones; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Immunomodulators; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis-associated respiratory tract infections; Idiopathic pulmonary fibrosis; Influenza virus infections; Respiratory tract disorders; Respiratory tract infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Asthma in USA (Inhalation, Powder)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation, Powder)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections(Prevention) in USA (Inhalation, Powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top